Eva, the U.S. guidelines center around the requisites used in the Stop Studies, which, with the exception of the single 50% dosage reduction during the UK Destiny Trial, don't include anything about dosage reduction, especially the highly successful gradual dosage reduction. During the Stop Studies, including the UK Destiny Trial, patients who failed their TFR attempt were restarted on the full dosage of their given TKI.
Although gradual dosage reduction has proven to be highly successful and very beneficial to the CML community, not all oncs/hemas, especially European oncs/hemas have gotten on board with it. The longer a CML patient is on the full dosage of any TKI, the higher the probability that they will suffer from the toxic side-effects. Dosage reduction lessens the probability of side-effects. After a CML patient has been either undetected, or plateaued, at a low CML level, for a prolonged period of time, generally, a year, or so, gradual dosage reduction can typically safely begin. Not all CML patients will reach TFR, but almost all can safely reduce their TKI dosage to a very low level.
Restarting on a low TKI dosage, after a failed TFR attempt, is relatively new but I haven't, as yet, seen anyone fail to regain their prior status when doing so. A few examples:
tiredblood
prior to TFR attempt, on Sprycel 20mg
03/11/2021 0.164% :(
04/07/2021 Restarted on Bosulif 100mg/day
04/16/2021 0.128%
05/17/2021 0.025%
08/12/2021 0.000%
shweflen
prior to TFR attempt, on Imatinib 300mg
11/17/2020 BCR-ABL:ABL = 0.026
11/24/2020 restarted on 100mg/day imatinib (onc recommended 300mg/day)
12/14/2020 BCR-ABL:ABL = 0.012
02/16/2021 BCR-ABL:ABL = 0.004
03/01/2021 started 100 mg imatinib every other day (record low 50mg/day dosage)
03/15/2021 BCR-ABL:ABL = Not Detected
05/19/2019 BCR-ABL:ABL = Not Detected
Debdoodah, on the U.S. LLS CML forum, will likely soon be restarting on Sprycel 20mg after a failed TFR attempt. Note: she had been undetected on Sprycel 20mg for a period of years.